Mildronate: An Antiischemic Drug for Neurological Indications

Wiley - Tập 11 Số 2 - Trang 151-168 - 2005
Nikolajs Sjakste1,2, Aleksandrs Gutcaits2, Ivars Kalvinsh2
1Faculty of Medicine, University of Latvia, Riga, Latvia
2Latvian Institute of Organic Synthesis, Riga, Latvia

Tóm tắt

ABSTRACTMildronate (3‐(2,2,2‐trimethylhydrazinium)propionate; MET‐88; meldonium, quaterine) is an antiischemic drug developed at the Latvian Institute of Organic Synthesis. Mildronate was designed to inhibit carnitine biosynthesis in order to prevent accumulation of cytotoxic intermediate products of fatty acid β‐oxidation in ischemic tissues and to block this highly oxygen‐consuming process. Mildronate is efficient in the treatment of heart ischemia and its consequences. Extensive evaluation of pharmacological activities of mildronate revealed its beneficial effect on cerebral circulation disorders and central nervous system (CNS) functions. The drug is used in neurological clinics for the treatment of brain circulation disorders. It appears to improve patients' mood; they become more active, their motor dysfunction decreases, and asthenia, dizziness and nausea become less pronounced. Since the brain does not utilize fatty acids as fuel other mechanisms of action of mildronate in CNS should be considered. Several reports indicate the possible existence of an alternative, non‐carnitine dependent mechanism of action of mildronate. Our recent findings suggest that CNS effects of mildronate could be mediated by stimulation of the nitric oxide production in the vascular endothelium by modification of the γ‐butyrobetaine and its esters pools. It is hypothesized that mildronate may increase the formation of the γ‐butyrobetaine esters. The latter are potent cholinomimetics and may activate eNOS via acetylcholine receptors or specific γ‐butyrobetaine ester receptors. This article summarizes known pharmacological effects of mildronate, its pharmacokinetics, toxicology, as well as the proposed mechanisms of action.

Từ khóa


Tài liệu tham khảo

Abeuov BA, 2004, Condition of the higher brain functions in patients with dyscirculatory encephalopathy treated with mildronate, Meditsina, 2, 78

Beketov AI, 2000, Comparative characteristics of cerebrovascular protective effects of mildronate, riboxine, and their combination during modeling of cerebral hemodynamics disturbance, Éksp Klin Farmakol, 63, 18

Belitskii GA, 1999, Absence of mutagenic and carcinogenic properties in mildronate, Vopr Onkol, 45, 279

Blium IaB, 1990, Influence of the Mildronate on intensity of the ADP‐ribosylation of chromatin proteins, Latv Zinatnu Akad Vestis, 8, 120

Blium Ia. B, 1987, Effect of quaterin and S‐methylmethionine on the intensity of chromatin protein methylation, Voen-Med Zh, 59, 18

Blium IaB, 1988, Stimulation with quaterin of DNA replication and repair, Voen-Med Zh, 60, 19

Blium IaB, 1990, Influence of the trimethylhydrazine analogue of gamma‐butyrobetaine — Mildronate — on the pre‐mRNA biosynthesis, Latv Zinatnu Akad Vestis, 10, 105

10.1536/ihj.30.743

10.1007/s00210-004-0925-6

10.1016/S1050-1738(02)00175-5

10.1023/B:MCBI.0000012853.20116.06

Dziak LA, 2003, Use of mildronate for the treatment of patients with circulatory encephalopathy against a background of stenosis of major arteries of the head, Lik Sprava, 5, 98

Dzintare M., 2004, Changes of concentration of nitric oxide in tissues under action of different pharmacological agents Summary of a Doctoral, 1

10.1080/10604450213832

Enina G, 1991, Medicinal effects and indications to mildronate application in neuroangiologic practice, Éksp Klin Farmakoter (Riga), 164

Frantsuzova SB., 1997, Pharmacodynamics of mildronate: A review, Zh Akad Med Nauk Ukr, 3, 612

Gaidar BV, 1989, Ways to optimize the cerebral circulation during extreme actions on the brain, Fiziol Zh Sechenova, 75, 1568

10.1023/A:1006849713407

10.1016/S0006-2952(00)00265-3

Germane S., 1991, Experimental study of mildronate effect on the central nervous system, Éksp Klin Farmakoter (Riga), 44

Germane S., 1991, Effect of mildronate on catecholamine level and somatic manifestations in white rats organs under stress, Éksp Klin Farmakoter (Riga), 51

10.1023/A:1007093926315

10.1248/bpb.23.770

Heidemanis K, 1990, Mildronate‐plasma membrane interaction mechanisms, Latv Zinatnu Akad Vestis, 11, 108

10.1211/002235702760345536

Hosein EA, 1970, The identification of acetyl‐L‐carnitylcholine in rat brain extracts and the comparison of its cholinomimetic properties with acetylcholine, Can J Physiol Pharmacol, 48, 709, 10.1139/y70-103

10.1016/0003-9861(64)90187-0

10.1097/00019501-200209000-00002

Kagan TI, 1991, Study of the effect of an inhibitor of carnitine‐dependent metabolism of mildronate on the oxidation of fatty acids in the liver mitochondria of intact rats, Vopr Med Khimii, 37, 44

Kalvinsh I., 1991, Synthesis and pharmacological activity of a new bioregulator mildronate, Éksp Klin Farmakoter (Riga), 7

KalvinshI VeverisM.Pharmaceutical composition for treating cardiovascular diseases containing 3‐(2 2 2‐trimethylhydrazinium) propionate and gamma‐butyrobetaine. US Pat. 5 859 056 Int. Cl.6 A61K3/205 01/12/1999.

Karpov RS, 1991, The clinical instrumental evaluation of treatment efficacy in patients with concomitant atherosclerosis of the coronary, cerebral and peripheral arteries, Ter Arkh, 634, 90

Kirimoto T, 1996, Beneficial effect of MET‐88, a gamma‐butyrobetaine hydroxylase inhibitor, on energy metabolism in ischemic dog hearts, Arch Int Pharmacodyn Ther, 331, 163

Klimkane L, 1992, The effect of mildronate on cancerogenesis and on the growth of transplanted tumours, Proc Latv Acad Sci B, 2, 54

Kuwajima M, 1999, Pharmacokinetic analysis of the cardioprotective effect of 3‐(2,2,2‐trimethylhydrazinium) propionate in mice: Inhibition of carnitine transport in kidney, J Pharmacol Exp Ther, 289, 93

10.1007/BF01270576

Logai IM, 1989, The use of lysosomotropic preparations in treating severe experimental chemical eye burns, Oftal'mol Zh, 8, 497

10.1023/B:BEBM.0000024380.24282.0b

Logunova LV, 1992, Studies on mildronate effect on the development and healing of stress ulcer stomach injuries in the experiment, Éksp Klin Farmakoter (Riga), 20, 82

Meerson FZ, 1995, Bioelectrical mechanism of the anti‐arrhythmia effect of a synthetic acetylcholine analogue EDIHYP, Kardiologiya, 31, 52

Moskalenko YE, 1999, Pharmacolgy of cerebral ischemia

Okunevich IV, 2002, Anti‐atherosclerotic action of mildronate in experiment, Patol Fiziol Éksp Ter, 2, 24

Orbidane O, 2004, Gamma‐butyrobetaine esterase activity in rat blood serum, Proc Latv Acad Sci B, 58, 98

Pcheliakov VF, 1987, Reparative post‐traumatic regeneration of the rabbit cornea after administration of quaterin, Oftal'mol Zh, 6, 369

Petersone I, 1991, Acute and chronic toxicity of mildronate, Éksp Klin Farmakoter (Riga), 67

Ratunova TM, 1989, The cardioprotective action of carnitine and its structural analog 3‐(2,2,2‐trimethylhydrazine)propionate on cardiac energy metabolism in experimental occlusion of the coronary artery in rats, Farmakol Toksikol, 52, 24

Rugaja Z, 1990, Effects of mildronate on experimental hepatic carcinogenesis, Latv Zinatnu Akad Vestis, 6, 122

10.1007/s00059-002-2428-x

Salnikov SN., 2002, Cytoprotector mildronate and cerebral oxygenation. Appendix for the Information edition of the Grindex for physicians pharmaceutists and specialists, ;2

Shutenko ZhV, 1995, Mildronate: Mechanisms of action, perspective for pathology correction, Khim-Pharm Zh, 29, 13

Shutenko Zh V, 1991, The effect of the carnitine biosynthesis inhibitor mildronate on the lipid metabolic indices of rats, Farmakol Toksikol, 542, 55

Shutenko Zh V, 1989, Regulation of carnitine‐dependent metabolism of fatty acids in the rat myocardium using 3‐(2,2,2‐trimethylhydrazinium) propionate, Vopr Med Khimii, 352, 59

Simkhovich BZ., 1988, Mildronate. Cardioprotector. A remedy increasing work efficiency, 1

Simkhovich BZ, 1986, Effect of a new structural analog of gamma‐butyrobetaine‐3‐(2,2,2‐trimethylhydrazine)propionate (THP) on carnitine level, carnitine‐dependent fatty acid oxidation and various indices of energy metabolism in the myocardium, Vopr Med Khimii, 324, 72

Simkhovich BZ, 1987, Biochemical characteristics of the anti‐ischemic action of the new structural analog of gamma‐butyrobetaine 3‐(2,2,2‐trimethylhydrazine)propionate, Farmakol Toksikol, 50, 100

10.1016/0006-2952(88)90717-4

Simkhovich BZ, 1987, Prevention of ischemic myocardial damage by reducing the intracellular free carnitine level, Kardiologiya, 27, 85

Sizova EN, 2002, The role of endogenous modulators of chemoreactivity in the regulation of coronary blood flow, Ross Fiziol Zh Sechenova, 88, 856

10.1111/j.1742-7843.2004.pto_940108.x

10.1016/j.ejphar.2004.05.006

Sjakste N, 1992, Modifications of the genome expression by several novel drugs, Exp Biol (Vilnius), 26, 3

10.1046/j.1432-1327.2001.02065.x

Suslina ZA, 2003, Antioxidant activity of mildronate and L‐carnitine in the treatment of patients with cerebrovascular diseases, Éksp Klin Farmakol, 66, 32

Thomizek WD, 1963, Über den Einfluß einiger Derivate aliphatischen Trimethylbetaine auf die Acetylcholine‐esterase und über die Hydrolyse von Betainestern, Acta Biol Med Germ, 11, 353

10.1016/S0300-9084(00)88891-4

10.1016/0006-2952(95)00019-V

10.1042/bj3610417

Vetra A, 1999, Significance of mildronate for improvement of results of early rehabilitation results of neurological patients, Latvijas Arstu Zurnals, 12, 33

Vinichuk SM., 1991, The efficacy of the mildronate treatment of patients with ischemic stroke, Vrach Delo, 7, 77

10.1007/s003950070032

Yoshisue K, 2000, Pharmacokinetics and biological fate of 3‐(2,2,2‐trimethylhydrazinium)propionate dihydrate (MET‐88), a novel cardioprotective agent, in rats, Drug Metab Dispos, 28, 687

Thông tin
Thông tin xuất bản

Wiley

Tập 11 Số 2

151-168

Thông tin tác giả